Agios Pharmaceuticals | AGIO - Des Atouts





Des Atouts Changement Date
AbbVie USD 133.96B 62M 2025-12
Agios Pharmaceuticals USD 1.3B 88.48M 2025-12
Alnylam Pharmaceuticals USD 4.97B 114.67M 2025-12
Amgen USD 90.59B 445M 2025-12
Arrowhead Research USD 1.6B 218.89M 2025-12
Astellas Pharma JPY 3.6T 153.62B 2025-12
AstraZeneca USD 114.07B 382M 2025-12
Bayer EUR 104.54B 331M 2025-12
Biogen USD 29.44B 232M 2025-12
BioMarin Pharmaceutical USD 7.59B 20.85M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Daiichi Sankyo JPY 3.82T 252.52B 2025-12
Eli Lilly USD 112.48B 2.46B 2025-12
Exelixis USD 2.84B 20.87M 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
GlaxoSmithKline GBP 61.12B 221M 2025-12
Incyte USD 6.96B 627.62M 2025-12
Ionis Pharmaceuticals USD 3.52B 490.91M 2025-12
Merck USD 129.55B 12.02B 2025-09
Moderna USD 12.34B 203M 2025-12
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Novartis USD 110.95B 3.66B 2025-12
Novartis USD 110.95B 3.66B 2025-12
Pfizer USD 208.73B 2.64B 2025-09
Puma Biotechnology USD 202.86M 7.95M 2025-09
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Roche Holding CHF 100.7B 5.94B 2025-12
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Vertex Pharmaceuticals USD 25.64B 780.7M 2025-12